Kasai M, Hatano S, Kitagawa M, Yoshimi A, Shirahase H, Nishimura K, Kakeya N
Research Laboratories, Kyoto Pharmaceutical Industries, Ltd., Japan.
J Antibiot (Tokyo). 1999 May;52(5):491-500. doi: 10.7164/antibiotics.52.491.
To improve the oral absorption of ceftizoxime (CZX), 7beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]- 3-cephem-4- carboxylic acid, we synthesized and evaluated a novel series of bifunctional prodrugs, in which L-alanine was introduced into the aminothiazole-oxime moiety at the C-7 position of the various lipophilic esters of CZX. Among these prodrugs, pivaloyloxymethyl 7beta-[(Z)-2-(2-(S)-alanylaminothiazol-4-yl)-2-methoxyiminoa cetamido]-3-cephem-4-carboxylate hydrochloride (ceftizoxime alapivoxil, AS-924) was well absorbed after oral administration in experimental animals and showed potent therapeutic effects in mice infected with gram-positive and gram-negative bacteria.
为提高头孢唑肟(CZX,7β-[(Z)-2-(2-氨基噻唑-4-基)-2-甲氧基亚氨基乙酰胺基]-3-头孢烯-4-羧酸)的口服吸收,我们合成并评估了一系列新型双功能前药,其中将L-丙氨酸引入到CZX各种亲脂性酯C-7位的氨基噻唑肟部分。在这些前药中,盐酸7β-[(Z)-2-(2-(S)-丙氨酰氨基噻唑-4-基)-2-甲氧基亚氨基乙酰胺基]-3-头孢烯-4-羧酸新戊酰氧甲酯(头孢唑肟阿洛匹酯,AS-924)在实验动物口服给药后吸收良好,对感染革兰氏阳性菌和革兰氏阴性菌的小鼠显示出强效治疗效果。